Events
Start of main content
Trailblazing in cancer immunotherapy
Life and Matter Sciences International Symposium October 29 - 31, 2017 Pamplona
General information
Venue: Museo Universidad de Navarra. Campus Universitario, s/n. Pamplona
Organized by:
Fundación Ramón Areces
In cooperation with:
Fundación para la Investigación Médica Aplicada, Clínica Universidad de Navarra
Coordinator/s:
Ignacio MeleroCentro de Investigación Médica Aplicada y Clínica Universidad de Navarra
Pedro BerraondoCentro de Investigación Médica Aplicada
José Luis Pérez Gracia Clínica Universidad de Navarra
- Description
- Programme
Immunotherapy strategies against cancer are emerging as powerful weapons for treatment of this disease. The success of checkpoint inhibitors against metastatic melanoma and adoptive T-cell therapy with chimeric antigen receptor T cells against B-cell-derived leukemias and lymphomas are only two examples of developments that are changing the paradigms of clinical cancer management.
These changes are a result of many years of intense research into complex and interrelated cellular and molecular mechanisms controlling immune responses. Promising advances come from the discovery of cancer mutation-encoded neoantigens, improvements in vaccine development, progress in delivery of cellular therapies, and impressive achievements in biotechnology.
As a result, radical transformation of cancer treatment is taking place in which conventional cancer treatments are being integrated with immunotherapeutic agents. Many clinical trials are in progress testing potential synergistic effects of treatments combining immunotherapy with other therapies and immunotherapies among themselves. Much remains to be learned about the selection, delivery, and off-target effects of immunotherapy used alone or in combination.
The existence of numerous escape mechanisms from the host immune system that human tumors have evolved still is a barrier to success. Efforts to understand the rules of immune cell dysfunction and of cancer-associated local and systemic immune suppression are providing new insights and fuel the enthusiasm for new therapeutic strategies. In the future, it might be possible to tailor immunotherapy for each cancer patient. The use of new immune biomarkers and the ability to assess responses to therapy by noninvasive monitoring promise to improve early cancer diagnosis and prognosis. Personalized immunotherapy based on individual genetic, molecular, and immune profiling is a potentially achievable future goal.
"The current excitement for immunotherapy is justified in view of many existing opportunities for harnessing the immune system to treat cancer", Clin Cancer Res; 22(8); 1845-55.©2016 AACR.
Now, is the time to find the next breakthroughs in our immunotherapy quest against cancer. Innovation is most needed than ever. In this meeting, researchers confronting the new frontiers of immunotherapy at the cutting edge of academic, clinical and industrial development will exchange and projects and ideas. Trail blazing is always hard but we need to bring forward more efficacious treatments.
Sunday, 29
15:30
Registration and congress documentation
16:15
Opening
Mariano Barbacid
Scientific Council. Fundación Ramón Areces.
Jesús San Miguel
Clínica Universidad de Navarra (CUN).
Ignacio Melero
Centro de Investigación Médica Aplicada (CIMA). Clínica Universidad de Navarra (CUN).
José Luis Pérez Gracia
Clínica Universidad de Navarra (CUN).
Pedro Berraondo
Centro de Investigación Médica Aplicada (CIMA).
16:30
Keynote lecture: Future of cancer immunotherapy: enhancement or normalization?
Lieping Chen
Yale. USA.
Chairmen:
Pedro Berraondo
Centro de Investigación Médica Aplicada (CIMA).
Ignacio Melero
Centro de Investigación Médica Aplicada (CIMA). Clínica Universidad de Navarra (CUN).
17:00
Break
18:00
Exploiting tumor antigenicity
Chairmen:
Juanjo Lasarte
Centro de Investigación Médica Aplicada (CIMA).
Pablo Sarobe
Centro de Investigación Médica Aplicada (CIMA).
The yin and yang of cancer immunotherapy combinations
Daniel Chen
Roche Genentech. USA.
18:40
Individualizing cancer immunotherapy
Özlem Türeci
Biontech. Germany
19:20
Cancer immunotherapy beyond PD-1: novel pathways and combinations
Andrea van Elsas
ADURO. Netherlands
20:00
Radiotherapy and immunotherapy shoulder to shoulder into the fray
Silvia Formenti
Cornell. USA
Monday, 30
9:00
Immunotherapy development: industrial view and pipelines (1)
Chairmen:
José Luis Pérez Gracia
Clínica Universidad de Navarra (CUN).
Felipe Calvo
Hospital Gregorio Marañón. Madrid.
Novel drug combinations for cancer immunotherapy
Nils Lonberg
Bristol-Myers Squibb (BMS). USA.
9:20
Medimmune cancer immunotherapy approach
Bahija Jallal
Medimmune. USA.
9:40
MSD cancer immunotherapy approach
David Kaufman.
Medical Stores Department (MSD).
10:00
Round table discussion
10:40
Break
11:00
Immunotherapy development: industrial view and pipelines (2)
Chairmen:
Luis Paz-Ares
Hospital Universitario Doce de Octubre. Madrid.
Luis Montuenga
Centro de Investigación Médica Aplicada (CIMA).
Advances in CAR T cell therapy: CD19 therapy and beyond
Jennifer Brogdon
Novartis. USA.
11:20
Building a next-generation immuno-oncology pipeline in a competitive space: perspectives from a "new kid on the block"
Lazslo Radvanyi
Merck Serono. USA.
11:40
A therapeutic strategy to target cold tumors
Eric Borges
Boehringer Ingelheim. Germany.
12:00
The Lilly immuno-oncology pipeline: enabling rational combinations
Michael Kalos
Lilly. USA.
12:20
Round table discussion
12:45
Break
14:00
Keynote lecture: clinical development of lung cancer immunotherapy
Luis Paz-Ares
Hospital Universitario Doce de Octubre. Madrid.
Chairs:
Ignacio Melero
Centro de Investigación Médica Aplicada (CIMA). Clínica Universidad de Navarra (CUN).
Ruth Vera
Hospital de Navarra.
14:30
Immunotherapy based on evidence
Chairs:
Rubén Pío
Centro de Investigación Médica Aplicada (CIMA).
María Rodríguez
Centro de Investigación Médica Aplicada (CIMA). Clínica Universidad de Navarra (CUN).
Targeting immune modulation at the tumour site
Sergio Quezada
University College London (UCL). UK.
15:10
Anti-cancer immune therapy of melanoma
Mario Sznol
Yale. USA.
15:50
Exploiting radiotherapy in immunotherapy combinations
Timothy Illidge
The University of Manchester. UK
16:30
Immunotherapy biomarkers, working in the tissue
Chairs:
Dolores Lozano
Clínica Universidad de Navarra (CUN).
Miguel Idoate
Clínica Universidad de Navarra (CUN).
Understanding the tumor immune composition using multiplexed quantitative approaches
Kurt Schalper
Yale. USA.
17:10
Diagnostics in the era of cancer immunotherapy
Priti Hegde
Roche Genentech. USA.
17:50
Role of immunotherapy in Hodgkin and non-Hodgkin lymphomas
Scott J. Rodig
Brigham and Women's Hospital. USA
Tuesday, 31
9:00
TNFR costimulation in action
Chairmen:
David Escors
Navarrabiomed.
Fernando Pastor
Centro de Investigación Médica Aplicada (CIMA)
CD40 stimulation: the rules of a complex game
Ann White
UCB Celltech. UK
9:40
Moving forward CD137-based immunotherapies
Ignacio Melero
Centro de Investigación Médica Aplicada (CIMA). Clínica Universidad de Navarra (CUN).
10:20
GITR and 4-1BB in chronic viral infection: implications for cancer therapy
Tania Watts
University of Toronto. Canada.
11:00
Break
11:30
Genetics and genetic intervention for better immunotherapies
Chairmen:
Cristian Smerdou
Centro de Investigación Médica Aplicada (CIMA).
Rubén Hernández Alcoceba
Centro de Investigación Médica Aplicada (CIMA).
Identification of immunoreactive microsatellite stable (MSS) colorectal cancer for potential immune interventions
Nicolás J. LLosa
Johns Hopkins. USA.
12:10
Deconstructing the T cell receptor signaling nanomachine
Balbino Alarcón
Centro de Biología Molecular (CBM).
12:50
Viruses and IFNα/ß in immunotherapy
Pedro Berraondo
Centro de Investigación Médica Aplicada (CIMA).
13:30
Viral gene therapies
Ramón Alemany
VCN.
14:10
Break
15:30
Exploiting new tools to improve immunotherapy
Chairs:
Susana Inogés
Clínica Universidad de Navarra (CUN).
Ignacio Gil Bazo
Clínica Universidad de Navarra (CUN).
Complement in cancer immunotherapy
Rubén Pío
Centro de Investigación Médica Aplicada (CIMA).
16:10
Patient-derived tumor models for immunotherapy development
Miguel Sanmamed
Yale. USA.
17:00
Identifying T cells specific against cancer
Alena Gros
Vall d´Hebron. Barcelona.
-
Activities related
-
Projects related
-
News related
-
4
Nov
2022
Session Red Nacional de Metástasis Cerebral (RENACER): Dos años de andadura conjunta. 2ª Asamblea general Madrid, Friday, 4 November 2022, 10:45 hours
-
16
Mar
2023
Conference Nuevas estrategias contra el cáncer: poner el carro delante de los caballos Madrid, Thursday, 16 March 2023, 19:00 hours
-
18
May
2023
Session Riesgo cardiovascular en largos supervivientes de cáncer infantil Madrid, Thursday, 18 May 2023, 9:30 hours
- Tumor microbiome and immune profiles as predictors of treatment response in high-risk non-muscle invasive bladder cancer (MIT-BC Study) 2020 Senior Researcher : Nuria Malats Riera y Ravid Straussman Research Centre or Institution : Centro Nacional de Investigaciones Oncológicas. Madrid y el Weizman Institute of Science. Rehovot
- Spanish National Brain Metastasis Network (RENACER): Implementation, Development and Coordination 2020 Senior Researcher : Eva Ortega Paíno Research Centre or Institution : Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid
- Exploring post-translational regulation of angiogenic and inflammatory-related processes during colorectal cancer progession and differential recurrence 2020 Senior Researcher : Petronila Penela Márquez Research Centre or Institution : Centro de Biología Molecular Severo Ochoa. CSIC - UAM
End of main content